



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

July 2, 2021

Eli Casdin  
Chief Executive Officer  
CM Life Sciences, Inc.  
c/o Corvex Management LP  
667 Madison Avenue  
New York, New York 10065

**Re: CM Life Sciences, Inc.**  
**Preliminary Merger Proxy Statement on Schedule 14A**  
**Filed May 6, 2021**  
**File No. 001-39482**

Dear Mr. Casdin:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Colin J. Diamond, Esq.